Sodium zirconium cyclosilicate
Crystal structure of ZS-9. Blue spheres = oxygen atoms, red spheres = zirconium atoms, green spheres = silicon atoms. | |
| Clinical data | |
|---|---|
| Trade names | Lokelma |
| Other names | ZS-9 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a618035 |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | Not absorbed |
| Excretion | Feces |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | (2Na·H2O·3H4SiO4·H4ZrO6)n |
Sodium zirconium cyclosilicate, sold under the brand name Lokelma, is a medication used to treat high blood potassium.[5] Onset of effects occurs in one to six hours.[5] It is taken by mouth.[5]
Common side effects include swelling and low blood potassium.[5] Use is likely safe in pregnancy and breastfeeding.[5] It works by binding potassium ions in the gastrointestinal tract which is then lost in the stool.[5][6]
Sodium zirconium cyclosilicate was approved for medical use in the European Union and in the United States in 2018.[5][4][7] It was developed by AstraZeneca.[5]
- ^ a b "Lokelma APMDS". Therapeutic Goods Administration (TGA). 24 May 2024. Retrieved 10 June 2024.
- ^ "Summary Basis of Decision (SBD) for Lokelma". Health Canada. 23 October 2014. Archived from the original on 31 May 2022. Retrieved 29 May 2022.
- ^ "Lokelma- sodium zirconium cyclosilicate powder, for suspension". DailyMed. 30 September 2022. Archived from the original on 5 December 2022. Retrieved 27 February 2023.
- ^ a b "Lokelma EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 8 January 2021. Retrieved 11 October 2019.
- ^ a b c d e f g h "Sodium Zirconium Cyclosilicate Monograph for Professionals". Drugs.com. Archived from the original on 1 August 2020. Retrieved 11 October 2019.
- ^ Hoy SM (October 2018). "Sodium Zirconium Cyclosilicate: A Review in Hyperkalaemia". Drugs. 78 (15): 1605–1613. doi:10.1007/s40265-018-0991-6. PMC 6433811. PMID 30306338.
- ^ "Drug Approval Package: Lokelma (sodium zirconium cyclosilicate)". U.S. Food and Drug Administration (FDA). 8 June 2018. Archived from the original on 13 April 2021. Retrieved 7 May 2020.